Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants

Vaccine

Volumn 31, Issue 5, 2013, Pages 777-783

  Madhi, Shabir A ^a,b,c   Izu, Alane ^b   Violari, Avye ^b   Cotton, Mark F ^d   Panchia, Ravindre ^b   Dobbels, Els ^d   Sewraj, Poonam ^b   van Niekerk, Nadia ^b,c   Jean Philippe, Patrick ^e   Adrian, Peter V ^b,c  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

Dosing schedules; HIV; Opsonophagocytic assay; Pneumococcal conjugate vaccine; Streptococcus pneumoniae

Indexed keywords

IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; MOTHER; OPSONIZATION; PERINATAL INFECTION; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; TREATMENT INDICATION; VACCINATION; VIRUS LOAD;

ANTIBODIES, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 84872620534     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.076     Document Type: Article

References (23)

1. Organisation W.H. Pneumococcal vaccines WHO position paper-2012. Wkly Epidemiol Rec 2012, 87(14):129-144.
2. Scott P., Rutjes A.W., Bermetz L., Robert N., Scott S., Lourenco T., et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine 2011, 29(52):9711-9721.
3. Ruckinger S., Dagan R., Albers L., Schonberger K., von Kries R. Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis. Vaccine 2011, 29(52):9600-9606.
4. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
5. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349(14):1341-1348.
6. Madhi S.A., Adrian P., Kuwanda L., Jassat W., Jones S., Little T., et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007, 25(13):2451-2457.
7. Madhi S.A., Kuwanda L., Cutland C., Holm A., Kayhty H., Klugman K.P. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005, 24(5):410-416.
8. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection; August 11, 2011. p. 1-268. Available at [accessed 14.08.12]. http://aidsinfo.nih.gov/ContentFiles/lvguidelines/PediatricGuidelines.pdf.
9. Madhi S.A., Adrian P., Cotton M.F., McIntyre J.A., Jean-Philippe P., Meadows S., et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010, 202(3):355-361.
10. Violari A., Cotton M.F., Gibb D.M., Babiker A.G., Steyn J., Madhi S.A., et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008, 359(21):2233-2244.
11. Goldblatt D., Southern J., Ashton L., Andrews N., Woodgate S., Burbidge P., et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr Infect Dis J 2010, 29(5):401-405.
12. Johnson H.L., Deloria-Knoll M., Levine O.S., Stoszek S.K., Freimanis Hance L., Reithinger R., et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010, 7.(10).
13. Madhi S.A., Petersen K., Madhi A., Wasas A., Klugman K.P. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000, 19(12):1141-1147.
14. Scott J.A., Ojal J., Ashton L., Muhoro A., Burbidge P., Goldblatt D. Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis 2011, 53(7):663-670.
15. Holmlund E., Nohynek H., Quiambao B., Ollgren J., Kayhty H. Mother-infant vaccination with pneumococcal polysaccharide vaccine: persistence of maternal antibodies and responses of infants to vaccination. Vaccine 2011, 29(28):4565-4575.
16. Poehling K.A., Talbot T.R., Griffin M.R., Craig A.S., Whitney C.G., Zell E., Lexau C.A., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006, 295(14):1668-1674.
17. Pelton S.I., Weycker D., Klein J.O., Strutton D., Ciuryla V., Oster G. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2010, 28(6):1575-1582.
18. van Gils E.J., Veenhoven R.H., Hak E., Rodenburg G.D., Bogaert D., Ijzerman E.P., et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 2009, 302(2):159-167.
19. Patrzalek M., Albrecht P., Sobczynski M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis 2010, 29(7):787-792.
20. Pirez M.C., Algorta G., Cedres A., Sobrero H., Varela A., Giachetto G., Montano A. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J 2011, 30(8):669-674.
21. Durando P., Crovari P., Ansaldi F., Sticchi L., Sticchi C., Turello V., et al. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009, 27(25/26):3459-3462.
22. Mphatswe W., Blanckenberg N., Tudor-Williams G., Prendergast A., Thobakgale C., Mkhwanazi N., et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS 2007, 21(10):1253-1261.
23. Kurewa E.N., Gumbo F.Z., Munjoma M.W., Mapingure M.P., Chirenje M.Z., Rusakaniko S., et al. Effect of maternal HIV status on infant mortality: evidence from a 9-month follow-up of mothers and their infants in Zimbabwe. J Perinatol 2010, 30(2):88-92.